Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: Mitigation and Management of Adverse Events

Trastuzumab deruxtecan plus pertuzumab improved systemic and intracranial outcomes in HER2-positive breast cancer with baseline brain metastases.

Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.

Relacorilant plus nab-paclitaxel and bevacizumab produced a 59% response rate in platinum-resistant ovarian cancer in Part A of the BELLA trial.

Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.

Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.

Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.

The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.

Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.